Firsekibart

伏欣奇拜单抗

Report date: 2026/04/28 20:00:22

Base Information

Drug NameFirsekibart
Drug Alias NameGenakumab injection金纳单抗Genakumab金蓓欣GenSci-048 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsSolid tumourssystemic sclerosis-associated interstitial lung diseasePain +[11] 
Global Approved IndicationsArthritis, Gouty
Approved Indications in ChinaArthritis, Gouty
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/30
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumourssystemic sclerosis-associated interstitial lung diseasePain +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A